title: An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.
abstract: The skeleton is the most common metastatic organ in patients with prostate cancer (PCa). Non-invasive biomarkers that can facilitate the detection and monitoring of bone metastases are highly desirable. We designed this study to assess the expression patterns of serum miR-141 in patients with bone-metastatic PCa. Serum samples were collected to measure the miR-141 level in 56 patients, including six with benign prostatic hyperplasia (BPH), 20 with localized PCa and 30 with bone-metastatic PCa (10 with hormone-naive PCa, 10 with hormone-sensitive PCa and 10 with hormone-refractory PCa). A bone scan was performed for each patient with PCa to assess the number of bone lesions. The quantification of serum miR-141 levels was assayed by specific TaqMan qRT-PCR. The results showed that serum miR-141 levels were elevated in patients with bone metastasis (P<0.001). There was no statistically significant difference in the serum miR-141 levels between patients with BPH and patients with localized PCa. Using Kendall's bivariate correlation test, both the Gleason score and the number of bone-metastatic lesions were found to correlate with serum miR-141 levels (P=0.012 and P<0.001, respectively). The serum miR-141 level was found to be positively correlated with alkaline phosphatase (ALP) level in patients with skeletal metastasis, using Pearson's bivariate correlation test. No relationship was found between the serum miR-141 level and the serum prostate-specific antigen (PSA) level. We concluded that serum miR-141 levels are elevated in patients with bone-metastatic PCa and that patients with higher levels of serum miR-141 developed more bone lesions. Furthermore, serum miR-141 levels are correlated with serum ALP levels but not serum PSA levels.
authors: Hai-Liang
authors: HL
authors: Zhang
authors: Xiao-Jian
authors: XJ
authors: Qin
authors: Da-Long
authors: DL
authors: Cao
authors: Yao
authors: Y
authors: Zhu
authors: Xu-Dong
authors: XD
authors: Yao
authors: Shi-Lin
authors: SL
authors: Zhang
authors: Bo
authors: B
authors: Dai
authors: Ding-Wei
authors: DW
authors: Ye
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D001859:Bone Neoplasms / Q000097:blood* / Q000235:genetics / Q000556:secondary*; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000235:genetics; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000235:genetics; D011471:Prostatic Neoplasms / Q000097:blood* / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C533895:MIRN141 microRNA, human; D035683:MicroRNAs; D017430:Prostate-Specific Antigen
references: J Orthop Res. 2005 Nov;23(6):1475-83
references: 16005175
references: Urol Oncol. 2012 Sep;30(5):607-13
references: 20888271
references: PLoS One. 2008 Sep 05;3(9):e3148
references: 18773077
references: J Urol. 2010 Jul;184(1):162-7
references: 20483155
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Prostate. 1999 Jan 1;38(1):28-34
references: 9973106
references: Methods Mol Biol. 2008;444:269-73
references: 18425488
references: Int J Cancer. 2011 Feb 1;128(3):608-16
references: 20473869
references: Cancer. 2006 Jul 15;107(2):289-98
references: 16752412
references: Endocr J. 1998 Feb;45(1):97-104
references: 9625452
references: Can J Urol. 2009 Feb;16(1):4472-7
references: 19222885
references: Br J Cancer. 2012 Feb 14;106(4):768-74
references: 22240788
references: Int J Cancer. 2012 Aug 1;131(3):652-61
references: 22052531
references: Br J Cancer. 2000 Feb;82(4):858-64
references: 10732759
references: N Engl J Med. 2008 Dec 18;359(25):2720-2
references: 19092157
references: J Pathol. 2011 Jan;223(2):102-15
references: 21125669
references: Asian J Androl. 2009 Jan;11(1):57-67
references: 19050684
references: Tumour Biol. 2011 Jun;32(3):583-8
references: 21274675
references: J Bone Miner Metab. 2001;19(1):45-51
references: 11156473
references: PLoS One. 2011 Mar 17;6(3):e17745
references: 21445232
references: Gynecol Oncol. 2008 Jul;110(1):13-21
references: 18589210
references: N Engl J Med. 1987 Oct 8;317(15):909-16
references: 2442609
references: BJU Int. 2008 May;101(9):1071-5
references: 18070191
references: Asian J Androl. 2009 Jan;11(1):22-7
references: 19050689
references: Oncogene. 2008 Jul 17;27(31):4373-9
references: 18372920
references: N Engl J Med. 2004 Oct 7;351(15):1502-12
references: 15470213
references: Eur Urol. 1998 Aug;34(2):142-7
references: 9693250
references: BJU Int. 2002 Jul;90(2):162-73
references: 12081758
references: J Urol. 2005 Nov;174(5):1794-7
references: 16217289
references: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references: 18663219